Evidence map›Paper›PMID 39373925›Full record

Trial reportAnnals of surgical oncology2025

Prognostic Impact of Thoracic Duct Resection in Patients Who Underwent Transthoracic Esophagectomy Following Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma: Exploratory Analysis of JCOG1109.

Satoru Matsuda, Hiroya Takeuchi, Ken Kato, Ryunosuke Machida, Yoshinori Ito, Yasuhiro Tsubosa, Hiroyuki Daiko, Kazuo Koyanagi, Takashi Ogata, Takashi Fukuda and 11 more

Abstract readRandomized Controlled TrialClinical Trial, Phase III
PubMed Publisher
In one paragraph

Trial report in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Satoru MatsudaDepartment of Surgery, Keio University School of Medicine, Tokyo, Japan.
Hiroya TakeuchiDepartment of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan. takeuchi@hama-med.ac.jp.
Ken KatoDepartment of Head and Neck and Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Ryunosuke MachidaJapan Clinical Oncology Group Data Center, National Cancer Center Hospital, Tokyo, Japan.
Yoshinori ItoDepartment of Radiation Oncology, Showa University School of Medicine, Tokyo, Japan.
Yasuhiro TsubosaDivision of Esophageal Surgery, Shizuoka Cancer Center, Nagaizumi, Japan.
Hiroyuki DaikoDepartment of Esophageal Surgery, National Cancer Center Hospital, Tokyo, Japan.
Kazuo KoyanagiDepartment of Gastroenterological Surgery, Tokai University School of Medicine, Isehara, Japan.
Takashi OgataDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Takashi FukudaDepartment of Gastrointestinal Surgery, Saitama Cancer Center, Saitama, Japan.
Takeo FujitaDivision of Esophageal Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
Tetsuya AbeDepartment of Gastroenterological Surgery, Aichi Cancer Center, Nagoya, Japan.
Takeo BambaDepartment of Gastroenterological Surgery, Niigata Cancer Center, Niigata, Japan.
Masayuki WatanabeDepartment of Gastroenterological Surgery, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Hirofumi KawakuboDepartment of Surgery, Keio University School of Medicine, Tokyo, Japan.
Yuichi ShibuyaDepartment of Gastroenterological Surgery, Kochi Health Science Center, Kochi, Japan.
Dai OtsuboDepartment of Gastroenterological Surgery, Hyogo Cancer Center, Akashi, Japan.
Tomokazu KakisitaDepartment of Surgery, Shikoku Cancer Center, Matsumoto, Japan.
Tadayoshi HashimotoJapan Clinical Oncology Group Data Center, National Cancer Center Hospital, Tokyo, Japan.
Keita SasakiJapan Clinical Oncology Group Data Center, National Cancer Center Hospital, Tokyo, Japan.
Yuko KitagawaDepartment of Surgery, Keio University School of Medicine, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough several studies have investigated whether thoracic duct (TD) resection improves prognosis, the conclusion remains controversial. JCOG1109 is a three-arm randomized phase III trial to confirm the survival advantage of docetaxel, cisplatin, 5-fluorouracil (DCF), and cisplatin plus 5-fluorouracil (CF) combined with radiotherapy (CF-RT) over CF as neoadjuvant treatment. The study aimed to evaluate the survival impact of TD resection and its association with neoadjuvant treatment and pathological response in patients enrolled in JCOG1109. PATIENTS AND

methodsClinicopathological factors, surgical results, and prognosis were compared between TD preserved and resected groups. The survival impact of TD resection was also evaluated in the subgroups on the basis of combinations of preoperative therapy and pathological response.

resultsBetween December 2012 and July 2018, 601 patients were randomized (CF/DCF/CF-RT; 199/202/200) in JCOG1109. Of them, 541 patients underwent esophagectomy (183/181/177), and TD was resected in 265 patients (93/91/81). For the entire cohort, TD resection was not a significant prognostic factor for overall survival in the multivariable analysis (HR 1.20, 95% CI 0.91-1.57). In the subgroup analyses by combinations of neoadjuvant treatment and pathological response, TD resected group had a significantly better overall survival compared with TD preserved group in patients who received DCF and achieved pathological response (HR 0.20, 95% CI 0.07-0.61).

conclusionsThe survival benefit of TD resection was not demonstrated in patients with surgically resectable esophageal squamous cell carcinoma enrolled in JCOG1109. The residual tumor burden after neoadjuvant treatment might be linked to the survival impact of TD resection.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaEsophagectomyNeoadjuvant TherapyThoracic DuctAgedCisplatinDocetaxelFemaleFluorouracilFollow-Up StudiesHumansMaleMiddle AgedPrognosisCisplatinDocetaxelFluorouracil

Identifiers

PMID39373925

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.